SEARCH

SEARCH BY CITATION

References

  • Addison CL, Hitt M, Kunsken D & Graham FL (1997). Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol 78, 16531661.
  • Cheng L, Sapieha P, Kittlerova P, Hauswirth WW & Di Polo A (2002). TrkB gene transfer protects retinal ganglion cells from axotomy-induced death in vivo. J Neurosci 22, 39773986.
  • Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA, Zabner J, Ghodsi A & Chiorini JA (2000). Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U SA 97, 34283432.DOI: 10.1073/pnas.050581197
  • Di Pasquale G, Davidson BL, Stein CS, Martins IS, Scudiero D, Monks A & Chiorini JA (2003). Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9, 13061312.DOI: 10.1038/nm929
  • Fischer D, He ZG & Benowitz LI (2004). Counteracting the Nogo receptor enhances optic nerve regeneration if retinal ganglion cells are in an active growth state. J Neurosci 24, 16461651.DOI: 10.1523/JNEUROSCI.5119-03.2004
  • Fitzsimons HL, Bland RJ & During MJ (2002). Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain. Methods 28, 227236.DOI: 10.1016/S1046-2023(02)00227-X
  • Flotte TR (2004). Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther 11, 805810.DOI: 10.1038/sj.gt.3302233
  • Gao GP, Alvira MR, Wang LL, Calcedo R, Johnston J & Wilson JM (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 99, 1185411859.DOI: 10.1073/pnas.182412299
  • Glover CPJ, Bienemann AS, Heywood DJ, Cosgrave AS & Uney JB (2002). Adenoviral mediated, high, level, cell-specific transgene expression: a syn1-wpre cassette mediates increased transgene expression with no loss of neuron specificity. Mol Ther 5, 509516.
  • Grimm D, Kay MA & Kleinschmidt JA (2003). Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1–6. Mol Ther 7, 839850.DOI: 10.1016/S1525-0016(03)00095-9
  • Heiduschka P & Thanos S (2000). Restoration of the retinofugal pathway. Prog Retin Eye Res 19, 577606.DOI: 10.1016/S1350-9462(00)00011-2
  • Hermening S, Kügler S, Bähr M & Isenmann S. (2004) Increased protein expression from adenoviral shuttle plasmids and vectors by insertion of a small chimeric intron. J Virol Methods(in press).
  • Klein RL, Hamby ME, Gong Y, Hirko AC, Wang S, Hughes JA, King MA & Meyer EM (2002). Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp Neurol 176, 6674.DOI: 10.1006/exnr.2002.7942
  • Kügler S, Kilic E & Bähr M (2003a). Human synapsin-1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. Gene Ther 10, 337347.DOI: 10.1038/sj.gt.3301905
  • Kügler S, Klöcker N, Kermer P, Isenmann S & Bähr M (1999). Transduction of axotomized retinal ganglion cells by adenoviral vector administration at the optic nerve stump: an in vivo model system for the inhibition of neuronal apoptotic cell death. Gene Ther 6, 17591767.DOI: 10.1038/sj.gt.3301000
  • Kügler S, Lingor P, Schöll U, Zolotukhin S & Bähr M (2003b). Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. Virology 311, 8995.DOI: 10.1016/S0042-6822(03)00162-4
  • Kügler S, Straten G, Kreppel F, Isenmann S, Liston P & Bähr M (2000). The X-linked inhibitor of apoptosis (XIAP) prevents cell death in axotomized CNS neurons in vivo. Cell Death Differ 7, 815824.DOI: 10.1038/sj.cdd.4400712
  • Malik JMI, Shevtsova Z, Bähr M & Kügler S (2004). Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer. Mol Ther (in press).
  • Opie SR, Warrington KH, Agbandje-McKenna M, Zolotukhin S & Muzyczka N (2003). Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 77, 69957006.DOI: 10.1128/JVI.77.12.6995-7006.2003
  • Paterna JC, Moccetti T, Mura A, Feldon J & Bueler H (2000). Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Ther 7, 13041311.DOI: 10.1038/sj.gt.3301221
  • Potter M, Chesnut K, Muzyczka N, Flotte T & Zolotukhin S (2002). Streamlined large-scale production of recombinant adeno-associated virus (rAAV) vectors. Methods Enzymol 346, 413430.
  • Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X & Samulski RJ (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76, 791801.DOI: 10.1128/JVI.76.2.791-801.2002
  • Reich SJ, Auricchio A, Hildinger M, Glover E, Maguire AM, Wilson JM & Bennett J (2003). Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. Hum Gene Ther 14, 3744.DOI: 10.1089/10430340360464697
  • Walters RW, Yi SMP, Keshavjee S, Brown KE, Welsh MJ, Chiorini JA & Zabner J (2001). Binding of adeno-associated virus type 5–2,3-linked sialic acid is required for gene transfer. J Biol Chem 276, 2061020616.DOI: 10.1074/jbc.M101559200
  • Weishaupt JH & Bähr M (2001). Degeneration of axotomized retinal ganglion cells as a model for neuronal apoptosis in the central nervous sys. Restor Neurol Neurosci 19, 1927.
  • Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ & Muzyczka N (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6, 973985.DOI: 10.1038/sj.gt.3300938